BR0112130A - Composições farmacêuticas e métodos para uso - Google Patents

Composições farmacêuticas e métodos para uso

Info

Publication number
BR0112130A
BR0112130A BR0112130-8A BR0112130A BR0112130A BR 0112130 A BR0112130 A BR 0112130A BR 0112130 A BR0112130 A BR 0112130A BR 0112130 A BR0112130 A BR 0112130A
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
aryl substituted
amines
nicotinic compounds
Prior art date
Application number
BR0112130-8A
Other languages
English (en)
Inventor
Gary Maurice Dull
Jean-Pierre Leconte
Humayun Kabir
Original Assignee
Targacept Inc
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc, Aventis Pharma Sa filed Critical Targacept Inc
Publication of BR0112130A publication Critical patent/BR0112130A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS E MéTODOS PARA USO". A presente invenção refere-se a pacientes susceptíveis ou que sofrem de condições e distúrbios, tais como distúrbios do sistema nervoso central, sendo tratados administrando a um paciente em necessidade deste composições que são sais de ácido 2,3-diaciltartárico de compostos nicotínicos, e particularmente, compostos nicotínicos que são caracterizados como aminas substituídas por arila (por exemplo, aminas olefínicas substituídas por arila).
BR0112130-8A 2000-07-14 2001-07-11 Composições farmacêuticas e métodos para uso BR0112130A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,743 US6432954B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
PCT/US2001/021872 WO2002005798A2 (en) 2000-07-14 2001-07-11 Pharmaceutical compositions for treating neurological disorders

Publications (1)

Publication Number Publication Date
BR0112130A true BR0112130A (pt) 2003-09-02

Family

ID=24470778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112130-8A BR0112130A (pt) 2000-07-14 2001-07-11 Composições farmacêuticas e métodos para uso

Country Status (16)

Country Link
US (1) US6432954B1 (pt)
EP (1) EP1311265B1 (pt)
JP (1) JP2004509851A (pt)
CN (2) CN1468100A (pt)
AT (1) ATE285773T1 (pt)
AU (2) AU2002222909B2 (pt)
BR (1) BR0112130A (pt)
CA (1) CA2415901A1 (pt)
DE (1) DE60108130T2 (pt)
HU (1) HUP0301553A3 (pt)
IL (3) IL153577A0 (pt)
NO (1) NO20030155L (pt)
NZ (1) NZ523606A (pt)
PL (1) PL360532A1 (pt)
WO (1) WO2002005798A2 (pt)
ZA (1) ZA200300135B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO2005102051A1 (de) * 2004-04-21 2005-11-03 Basf Aktiengesellschaft Fungizide mischungen
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2007134038A2 (en) * 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
WO2009018373A2 (en) * 2007-07-31 2009-02-05 Targacept, Inc. Transdermal administration of (2s) - (4e) -n-methyl-5- (3- ( 5-is0pr0p0xypyridin) yl) -4-penten-2-amine
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
ZA957746B (en) * 1994-09-14 1996-07-25 Lundbeck & Co As H Carbamoyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
JP3603177B2 (ja) * 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
CA2709735A1 (en) * 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
DE10032456A1 (de) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Also Published As

Publication number Publication date
ZA200300135B (en) 2004-04-06
WO2002005798A2 (en) 2002-01-24
CA2415901A1 (en) 2002-01-24
EP1311265A2 (en) 2003-05-21
DE60108130T2 (de) 2006-02-23
NZ523606A (en) 2004-12-24
JP2004509851A (ja) 2004-04-02
US6432954B1 (en) 2002-08-13
PL360532A1 (en) 2004-09-06
EP1311265B1 (en) 2004-12-29
CN1680326A (zh) 2005-10-12
NO20030155L (no) 2003-03-13
AU2290902A (en) 2002-01-30
IL153577A0 (en) 2003-07-06
IL192287A0 (en) 2008-12-29
AU2002222909B2 (en) 2005-12-15
IL153577A (en) 2009-07-20
HUP0301553A2 (hu) 2003-08-28
CN1468100A (zh) 2004-01-14
ATE285773T1 (de) 2005-01-15
HUP0301553A3 (en) 2005-05-30
NO20030155D0 (no) 2003-01-13
WO2002005798A3 (en) 2003-03-13
DE60108130D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0307631A (pt) Piridinonas substituìdas como moduladores de p38 map-quinase
IL192287A0 (en) Pharmaceutical compositions and methods for use
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
PT751939E (pt) Naftilamidas como agentes para o sistema nervoso central
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BRPI0607918A2 (pt) tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia.
BR0112131A (pt) Composições farmacêuticas e métodos para uso
BRPI0518693A2 (pt) pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.